Browse Articles

Filter By:

  • Vitamin D is precursor of the steroid hormone calcitriol and has important functions throughout the body, including increasing intestinal absorption of calcium, magnesium and phosphate. Vitamin D deficiency has been linked with a range of disorders, including several bone diseases. However, large trials of vitamin D supplementation have produced mixed results. Here, experts from around the world discuss several key questions in the vitamin D research and clinical fields.

    • Andrea Giustina
    • Marise Lazaretti-Castro
    • Inez Schoenmakers
    Viewpoint
  • The protein complex mTORC1 is a key regulator of cellular metabolism in response to energy availability. This Review discusses the role of mTORC1 in regulating energy expenditure and the implications for the development and treatment of obesity.

    • Camille Allard
    • Cristina Miralpeix
    • Daniela Cota
    Review Article
  • Schuermans et al. report phospholipase A and acyltransferase 3 (PLAAT3) deficiency in patients with lipodystrophy and peripheral neuropathy. Their discovery adds to the growing list of genetic lipodystrophies due to deficiencies of enzymes involved in phospholipid biosynthesis, including 1-acylglycerol-3-phosphate O-acyltransferase 2 and choline phosphate cytidylyltransferase 1 A.

    • Anil K. Agarwal
    • Abhimanyu Garg
    News & Views
  • Organoid technologies are a potent tool for investigating human biology, modelling diseases and developing novel therapies. In this Viewpoint, experts in metabolic and endocrine research in the brain, pituitary, skeletal muscle, bone and gastrointestinal system discuss how organoids and related bioengineered systems are currently used in their field and how innovations in these technologies could transform future research.

    • Penney M. Gilbert
    • Sandra Hofmann
    • James M. Wells
    Viewpoint
  • In this Review, the emerging cellular and molecular mechanisms by which obesity impairs key aspects of immunity are discussed, including changes in the abundance of key hormones, dysregulation of adipose-tissue-derived extracellular vesicles and dysregulation of polyunsaturated fatty acid metabolism.

    • Saame Raza Shaikh
    • Melinda A. Beck
    • Nancie J. MacIver
    Review Article
  • This Review describes a promising, bidirectional role for ghrelin in the interaction between circadian rhythms and metabolism. The authors explore how ghrelin affects outputs of circadian rhythm — including neuronal activity, circulating growth hormone levels, locomotor activity and eating behaviour — and discuss how circadian rhythms influence ghrelin expression.

    • Soumya S. Kulkarni
    • Omprakash Singh
    • Jeffrey M. Zigman
    Review Article
  • This Review describes the luteal phase of natural menstrual cycles and in vitro fertilization (IVF) cycles. The authors highlight the need for luteal phase support during IVF, outlining various luteal phase support regimens, mechanisms for luteal phase deficiency and potential biomarkers of endometrial receptivity.

    • Akanksha Garg
    • Agata P. Zielinska
    • Ali Abbara
    Review Article
  • This Review discusses notable discoveries in pituitary stem cell function and highlights important areas for current and future research, including the use of pituitary organoids for the advancement of pituitary stem cell biology and pituitary organogenesis as well as potential therapeutic approaches.

    • María Inés Pérez Millán
    • Leonard Y. M. Cheung
    • Sally A. Camper
    Review Article
  • The metabolic dysfunction that characterizes obesity and type 2 diabetes mellitus affects not only the heart and kidneys, but also the liver. Although lifestyle modification remains the cornerstone in the management of metabolic liver diseases, the field has progressed this year, with a new definition, validation of non-invasive biomarkers and numerous clinical trials.

    • Jean-François Dufour
    Year in Review
  • The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.

    • Mette M. Rosenkilde
    Year in Review
  • The pathophysiology of endometriosis is underpinned by a complex interplay of inflammatory processes that are responsible for the local and systemic effects of the condition. Recent studies delve further into this inflammatory interplay; using animal models, they identify potential therapeutic tools and remind us to look beyond the endometriotic lesions.

    • Jane E. Girling
    Year in Review
  • One hundred years after the Nobel prize was bestowed on Banting and McLeod for the ‘discovery’ of insulin, we are again seeing major evolutions in the management of type 1 diabetes mellitus, with the prospect of achieving disease control beyond mere management now becoming real. Here, we discuss the latest, most notable developments.

    • Pieter-Jan Martens
    • Chantal Mathieu
    Year in Review